Carrier screening by next‐generation sequencing: health benefits and cost effectiveness
Open Access
- 29 January 2016
- journal article
- research article
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 4 (3) , 292-302
Abstract
Background: Compared with conventional genotyping, which typically tests for a limited number of mutations, next‐generation DNA sequencing (NGS) provides increased accuracy for carrier screening. The objective of this study was to evaluate the cost effectiveness of carrier screening using NGS versus genotyping for 14 of the recessive disorders for which medical society guidelines recommend screening.Methods: Data from published literature, population surveys, and expert opinion were used to develop a decision tree model capturing decisions and outcomes related to carrier screening and reproductive health.Results: Modeling a population of 1,000,000 couples that was representative of the United States population and that contained 83,421 carriers of pathogenic mutations, carrier screening using NGS averted 21 additional affected births as compared with genotyping, and reduced costs by approximately $13 million. As compared with no screening, NGS carrier screening averted 223 additional affected births. The results are sensitive to assumptions regarding mutation detection rates and carrier frequencies in multiethnic populations.Conclusion: This study demonstrated that NGS‐based carrier screening offers the greater benefit in clinical outcomes and lower total healthcare cost as compared with genotyping.Keywords
Funding Information
- Good Start Genetics, Inc.
This publication has 37 references indexed in Scilit:
- ACMG position statement on prenatal/preconception expanded carrier screeningGenetics in Medicine, 2013
- Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US populationThe Journal of Maternal-Fetal & Neonatal Medicine, 2013
- Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation SequencingScience Translational Medicine, 2011
- Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseasesHuman Mutation, 2010
- ACOG Committee Opinion No. 442: Preconception and Prenatal Carrier Screening for Genetic Diseases in Individuals of Eastern European Jewish DescentObstetrics & Gynecology, 2009
- Economic evaluation of cystic fibrosis screening: A review of the literatureHealth Policy, 2008
- Carrier screening in individuals of Ashkenazi Jewish descentGenetics in Medicine, 2008
- Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panelGenetics in Medicine, 2004
- A Mutation ofPCDH15among Ashkenazi Jews with the Type 1 Usher SyndromeNew England Journal of Medicine, 2003
- Prenatal screening for cystic fibrosis: 5 years' experience reviewedThe Lancet, 1996